- Company
- Samsung Bioepis' biosimilar had ₩1.5 trillion
- by Chon, Seung-Hyun Feb 22, 2022 05:54am
- Biosimilar products developed by Samsung Bioepis generated 1.5 trillion won in sales overseas last year. It increased by more than 10% from the previous year, the largest ever. According to Samsung Bioepis on the 18th, five biosimilars recorded a total of $1.255.1 billion (about 1.5 trillion won) in overseas markets last year. It achieved
- Company
- Kymriah is expected to be able to register insurance benefit
- by Eo, Yun-Ho Feb 21, 2022 05:59am
- Kymriah, an ultra-high-priced one-shot treatment, is expected to be covered by insurance benefits as early as April. According to related industries, Novartis Korea's CAR-T new drug Kymriah officially began drug price negotiations with NHIS in the last week of the same month after passing the Drug Benefit Evaluation Committee of the HIRA on J
- Price of ‘Vesicare’ drops below its generics
- by Lee, Tak-Sun Feb 21, 2022 05:58am
- The voluntary price cut made by the overactive bladder treatment Vesicare (solifenacin succinate) is expected to reduce its drug price to a level lower than its generic versions. On what tactic the generic companies will take after losing their price competitivity remains the focus of attention. According to industry sources on the 20t
- Policy
- Required PMS case reports reduced for Genvoya and Descovy
- by Lee, Hye-Kyung Feb 21, 2022 05:58am
- The number of evidence cases reported for post-marketing surveillance of HIV treatments ‘Genvoya tab (emtricitabine / tenofovir alafenamide/ cobicistat / elvitegravir)’ and ‘Descovy tab (emtricitabine / tenofovir alafenamide) that are subject to reevaluation will be adjusted. Genvoya and Descovy, which received marketing authorization from
- Policy
- Pre-registration of Novavax vaccination will begin
- by Kim, Jung-Ju Feb 21, 2022 05:58am
- The quarantine authorities will start pre-registration of Novavax vaccinations for adults over the age of 18. According to the COVID-19 vaccination promotion team, adults over the age of 18 who want to receive Novavax can make reservations through (http://ncvr.kdca.go.kr). Elderly people who have difficulty making reservations on their own
- Company
- Development of Xolair biosimilars is in full swing
- by Ji Yong Jun Feb 21, 2022 05:58am
- Domestic and foreign bio companies have started to develop Xolair (Omalizumab) biosimilars which patents expire in two years. The development stage of Celltrion, a domestic company, is the fastest. According to Clinical Trials, a clinical registration site of the NIH on the 17th, six clinical trials of Xolair biosimilars are currently registe
- Company
- Vitrakvi's price negotiation has been extended
- by Eo, Yun-Ho Feb 18, 2022 05:55am
- According to related industries, both Roche's Rozlytrek (NTRK) anticancer drugs, Roche Korea's Rozlytrek and Bayer Korea's Vitrakvi, failed to conclude discussions with the NHIS (60 days) in January. The two drugs seeking the PE system passed the HIRA's Drug Benefit Evaluation Committee last year, but are in the final stage. If the extende
- Policy
- Tagrisso’s succeeds in RSA renewal… 3% price cut per dose
- by Kim, Jung-Ju Feb 18, 2022 05:55am
- AstraZeneca’s NSCLC treatment Tagrisso (Osimertinib) succeeded in renewing its risk-sharing agreement (RSA) with the National Health Insurance Service, and the price of the drugs will be adjusted and discounted by 3% per dose. According to industry sources, AstraZeneca has agreed to discount the insurance price of Tagrisso during RSA renegot
- Company
- AstraZeneca wins second trial on ‘Forxiga substance patent'
- by Kim, Jin-Gu Feb 18, 2022 05:55am
- AstraZeneca, the original drug maker of the SGLT-2 inhibitor for the treatment of diabetes, ‘Forxiga,’ won the second trial over its substance patent. The ruling has abruptly put a hold on Dong-A ST’s plans for the early release of its Forxiga latecomer. The industry interpreted this as a crisis for the ‘pro-drug strategy’ that has b
- Company
- The industry is worried about the spread of Omikron
- by Kim, Jin-Gu Feb 18, 2022 05:55am
- The Omicron mutation COVID-19 virus is also hurting factories and research institutes of pharmaceutical bio companies. Concerns are growing over production disruptions as a series of confirmed cases have emerged in Hwaseong Hyangnam Pharmaceutical Industrial Complex and Cheongju Osong Life Science Complex, where pharmaceutical factories are
